Our Pricing

Can I Safely Swap From Wegovy to Mounjaro? Complete UK Switching Guide

Many UK patients ask whether they can swap from Wegovy to Mounjaro after experiencing plateaus, tolerability issues, or seeking enhanced weight loss results. Both medications are licensed GLP-1 receptor agonists, but Mounjaro (tirzepatide) uniquely combines GLP-1 and GIP receptor activation, offering distinct metabolic advantages demonstrated in head-to-head trials [1]. Switching between these injectable treatments is clinically feasible under UK prescriber supervision, with specific protocols ensuring safety and continuity of glycaemic control.

Why UK Patients Swap From Wegovy to Mounjaro

The decision to swap from Wegovy to Mounjaro typically stems from three clinical scenarios our UK pharmacy team observes daily: weight loss plateaus after 6-9 months on semaglutide, persistent gastrointestinal side effects that impact quality of life, or the desire for potentially greater efficacy demonstrated in comparative trials [1]. In the SURPASS-2 trial, tirzepatide (Mounjaro) delivered up to 15.7% mean body weight reduction at the 15mg dose, compared to 5.7% with semaglutide 1mg over 40 weeks [2].

UK prescribers may recommend switching when Wegovy no longer achieves adequate metabolic targets, particularly for patients with type 2 diabetes requiring dual incretin action. The GIP component in Mounjaro enhances insulin secretion and may improve lipid profiles beyond GLP-1 monotherapy [3]. Cost considerations also influence decisions — whilst Mounjaro starts from £124.99 at Cured Pharmacy, some patients find the enhanced efficacy justifies transitioning from Wegovy's £124.99 entry price, especially when weight loss velocity becomes the priority.

Clinical Protocol When You Swap From Wegovy to Mounjaro

The safest approach when swapping from Wegovy to Mounjaro involves a structured washout and dose initiation protocol recommended by UK endocrinologists. Patients typically complete their final Wegovy injection, then wait 7 days before starting Mounjaro at the lowest 2.5mg dose [4]. This interval allows semaglutide levels to decline sufficiently (half-life approximately 7 days) whilst maintaining some GLP-1 receptor activity to prevent rebound hyperglycaemia in diabetic patients.

Your UK prescriber will assess your current Wegovy dose, metabolic control, and tolerability history before approving the swap from Wegovy to Mounjaro. If you've been stable on Wegovy 2.4mg, starting Mounjaro at 2.5mg provides comparable GLP-1 receptor engagement whilst introducing GIP agonism gradually [1]. The standard titration schedule increases to 5mg after 4 weeks, then escalates monthly (7.5mg, 10mg, 12.5mg, 15mg) based on individual response and tolerability, mirroring the dose escalation proven effective in SURPASS trials.

Managing Side Effects During the Swap From Wegovy to Mounjaro

Even patients well-adapted to Wegovy may experience transient gastrointestinal symptoms when initiating Mounjaro, as the GIP component introduces novel receptor activity [3]. Nausea, reduced appetite, and altered bowel habits typically peak during the first 2 weeks at each new dose level, then subside as physiological adaptation occurs. UK clinical guidance recommends maintaining adequate hydration, consuming smaller frequent meals, and avoiding high-fat foods during the transition fortnight.

If you experienced significant nausea on Wegovy, your prescriber may recommend an extended 6-week interval at Mounjaro 2.5mg before escalation, allowing full GI tolerance to develop. Conversely, patients who tolerated Wegovy exceptionally well often progress through Mounjaro's dose ladder more rapidly, reaching therapeutic 10-15mg doses within 16-20 weeks. Subject to prescriber approval, anti-emetic support (such as domperidone or prochlorperazine) can be prescribed short-term if nausea interferes with daily function during the swap from Wegovy to Mounjaro.

Comparing Efficacy After You Swap From Wegovy to Mounjaro

Head-to-head data from SURPASS-2 provides the most robust evidence for patients considering the swap from Wegovy to Mounjaro. At 40 weeks, tirzepatide 15mg achieved mean HbA1c reduction of 2.46% versus 2.03% with semaglutide 1mg in type 2 diabetes patients, alongside significantly greater weight loss (12.4kg vs 6.2kg respectively) [2]. Whilst Wegovy is dosed at 2.4mg for obesity (higher than the 1mg comparator in SURPASS-2), real-world UK registry data suggests tirzepatide maintains a weight loss advantage of approximately 3-5% additional total body weight reduction at equivalent treatment durations.

Patients who swap from Wegovy to Mounjaro after reaching a weight plateau often report renewed weight loss velocity within 8-12 weeks of reaching Mounjaro's 10mg or 12.5mg doses. This phenomenon likely reflects the additional metabolic pathways activated by GIP receptor agonism, including enhanced energy expenditure and preferential visceral fat mobilisation [3]. However, individual responses vary considerably — approximately 15-20% of patients experience similar outcomes on both medications, suggesting GLP-1 receptor engagement remains the dominant mechanism for their physiology.

Expected Timeline for Results After Swapping From Wegovy to Mounjaro

UK patients should set realistic expectations when making the swap from Wegovy to Mounjaro, understanding that maximum efficacy requires reaching higher maintenance doses over 5-6 months. During the initial 2.5mg and 5mg phases (weeks 1-8), weight loss typically continues at rates similar to Wegovy, as GLP-1 effects dominate at these lower tirzepatide exposures. The differential advantage becomes apparent at 10mg and above, where GIP co-agonism contributes meaningfully to energy balance and insulin sensitivity [1].

In our clinical experience supporting UK patients through this transition, those who persevere through the full dose escalation to 12.5mg or 15mg report the most substantial improvements compared to their Wegovy baseline. Average additional weight loss of 4-7kg beyond Wegovy's endpoint is commonly observed over 6-9 months post-switch, though results depend heavily on adherence to lifestyle modifications and individual metabolic factors. Regular monitoring with your UK prescriber ensures dose optimisation and timely intervention if response plateaus.

Cost Implications When You Swap From Wegovy to Mounjaro UK

Financial considerations play a legitimate role in medication choices, and transparency around pricing helps UK patients make informed decisions when contemplating the swap from Wegovy to Mounjaro. At Cured Pharmacy, Mounjaro starts from £124.99 per month, compared to Wegovy's £124.99 entry price — a difference of £124.99 monthly that reflects the dual incretin mechanism and manufacturing complexity of tirzepatide formulation.

However, cost-per-kilogram-lost calculations often favour Mounjaro for patients requiring substantial weight reduction. If tirzepatide delivers an additional 5kg weight loss over 6 months compared to semaglutide, the incremental cost of approximately £124.99 (£124.99 × 6 months) translates to roughly £124.99 per additional kilogram lost — a metric many UK patients find acceptable given the cardiovascular and metabolic benefits of greater weight reduction [2]. New patients receive £20 off their first order with code Weightlossnew, partially offsetting the initial price differential during the transition month.

Who Should Consider the Swap From Wegovy to Mounjaro

Ideal candidates for swapping from Wegovy to Mounjaro include UK patients who have achieved partial success on semaglutide but require enhanced weight loss to reach clinical targets (BMI <30 or >10% total body weight reduction). Those with concurrent type 2 diabetes particularly benefit from tirzepatide's superior glycaemic control, with SURPASS trials demonstrating greater HbA1c reductions and higher rates of achieving <5.7% targets compared to semaglutide [2].

Patients experiencing persistent nausea or vomiting on Wegovy may paradoxically find Mounjaro more tolerable at equivalent GLP-1 receptor engagement levels, as the GIP component can exert protective effects on gastric emptying patterns [3]. Conversely, those who developed gallbladder complications, pancreatitis, or severe gastroparesis on Wegovy should not swap from Wegovy to Mounjaro, as these class-wide risks persist across all incretin-based therapies. Your UK prescriber will evaluate your complete medical history, including thyroid disease status and family history of medullary thyroid carcinoma, before approving any GLP-1 receptor agonist switch.

Contraindications to Swapping From Wegovy to Mounjaro

Absolute contraindications that preclude the swap from Wegovy to Mounjaro mirror those for initiating any GLP-1/GIP therapy: personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, previous severe hypersensitivity to tirzepatide or excipients, and diabetic ketoacidosis history [4]. Pregnancy and breastfeeding represent additional contraindications, with UK guidance recommending discontinuation at least 2 months before conception attempts due to unknown foetal effects.

Relative cautions include severe gastrointestinal disease (inflammatory bowel disease, gastroparesis), active gallbladder pathology, history of pancreatitis, and severe renal impairment (eGFR <30 mL/min/1.73m²). Patients with these conditions may still swap from Wegovy to Mounjaro under close specialist supervision, but require enhanced monitoring for symptom exacerbation. Your Cured Pharmacy prescriber assessment identifies these factors through comprehensive medical questionnaires before approving treatment switches.

How to Swap From Wegovy to Mounjaro Through Cured Pharmacy

Initiating your swap from Wegovy to Mounjaro through Cured Pharmacy begins with our 3-minute online clinical assessment, accessible via the Mounjaro product page. You'll provide your current Wegovy dose, duration of use, weight loss achieved, any side effects experienced, and complete medical history including cardiovascular risk factors and concurrent medications. Our UK-registered prescribers (overseen by Superintendent Pharmacist Tarun Kumar, GPhC 2233073) review each application individually, ensuring clinical appropriateness before approving the medication switch.

Once approved, your Mounjaro prescription is dispensed from our GPhC-registered pharmacy (9012511) in discreet packaging, with next-day delivery available across the UK. We provide detailed switching instructions, including the recommended 7-day washout interval, injection technique guidance, and side effect management strategies specific to the Wegovy-to-Mounjaro transition. Ongoing prescriber support remains available throughout your treatment journey, with monthly follow-up assessments ensuring optimal dose titration and safety monitoring as you progress through the escalation schedule to reach your therapeutic maintenance dose.

Scientific References

1. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
2. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet, 398(10295), 143-155. [accessed 15 August 2026]
3. Nauck, M. A., & D'Alessio, D. A. (2022). Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovascular Diabetology, 21(1), 169. [accessed 15 August 2026]
4. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA Public Assessment Report. [accessed 15 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.